iShares Biotechnology ETF
307 hedge funds and large institutions have $4.31B invested in iShares Biotechnology ETF in 2014 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 81 increasing their positions, 117 reducing their positions, and 41 closing their positions.
46% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 41
6% more funds holding
Funds holding: 289 → 307 (+18)
4% less capital invested
Capital invested by funds: $4.49B → $4.31B (-$175M)
30% less funds holding in top 10
Funds holding in top 10: 20 → 14 (-6)
31% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 117
35% less call options, than puts
Call options by funds: $441M | Put options by funds: $677M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$81.2M |
| 2 |
Morgan Stanley
New York
|
+$66.5M |
| 3 |
SG Americas Securities
New York
|
+$51.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21M |
| 5 |
HI
Honeywell International
Charlotte,
North Carolina
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$231M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$217M |
| 3 |
Barclays
London,
United Kingdom
|
-$69.1M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$68.7M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$52.7M |
IBB Hedge Fund Activity: Q2 2014 in Review
307 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2014, worth a combined $4.31B — down 3.9% from $4.49B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new IBB positions and 41 closed out — a net gain of 19 holders — while 81 added to existing stakes and 117 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $81.2M. The largest seller was Citigroup, cutting an estimated $231M.
- 307 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2014, up from 289 in Q1 2014.
- Funds reported $4.31B of iShares Biotechnology ETF stock for Q2 2014, down 3.9% quarter-over-quarter.
- 60 funds opened new iShares Biotechnology ETF positions in Q2 2014 and 41 closed out, a net change of +19 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2014 was Goldman Sachs, an estimated $81.2M added.
- The largest iShares Biotechnology ETF seller in Q2 2014 was Citigroup, an estimated $231M sold.
Based on aggregated 13F filings for Q2 2014.